Becton, Dickinson and Co (BD), through its BD Biosciences segment has announced the US clearance and release of the BD FACSCanto™ flow cytometer for in vitro diagnostic use. This new benchtop analyzer now supports not only life science and clinical research applications, but also the routine and complex tests performed in clinical laboratories. The system was CE-IVD marked and released in Europe earlier this year.
The BD FACSCanto system, designed to assist clinical labs in achieving quality data quickly and efficiently, offers users high fluorescence sensitivity, minimal sample contamination, and processing speeds of up to 10,000 events per second. The system also facilitates rare event analysis, an important feature for clinical diagnostic laboratories.
“We leveraged our 30-plus years of expertise in flow cytometry in the design of the BD FACSCanto system,” says Bill Rhodes, vice president and general manager, BD Biosciences Immunocytometry Systems. “It incorporates many technology advances first developed in our BD™ LSR II expandable cell analyzer and our BD FACSAria™ cell sorter, and we are proud to deliver such an advanced, yet easy-to-use, system to the clinical diagnostics market.”
The BD FACSCanto system offers clinical laboratories the opportunity to increase efficiency and productivity. For example, the system has a fixed optical alignment, so users are not required to manually align lasers, and the fluidics cart holds all fluids necessary for routine operation and maintenance. The self-contained design facilitates automated cleaning, start-up, and shutdown routines, allowing clinical laboratories to concentrate on analysis and reporting of data. The system also provides automated sample loading with the BD FACS™ loader option. This enables walkaway sample acquisition, which provides laboratory personnel with more time to focus on other tasks.